RayzeBio Expands Leadership Team with Arvind Kush as Chief Financial Officer; and Aubrey Haddach, J.D., as General Counsel

January 24, 2022 at 08:00 AM EST

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the addition of Arvind Kush and Aubrey Haddach to its senior management team.

Arvind Kush – Chief Financial Officer. With over 13 years as an investment banker, Arvind joins RayzeBio from Bank of America Securities. Previously, he was a Managing Director in the healthcare investment banking group, advising biotechnology companies on financing and strategic initiatives. Arvind has worked on over $100 billion in M&A transactions and over $12 billion in equity and equity-linked capital raises.

Aubrey Haddach, J.D. – General Counsel and Secretary. Aubrey has over 25 years of combined industry experience beginning in laboratory chemistry and then transitioning into law in 2001. Before joining RayzeBio, her prior roles included General Counsel, Corporate Secretary, and Chief Privacy Officer at private and public companies. From 2003 to 2018, Aubrey was outside counsel to a variety of clients ranging from small businesses to Fortune 500 companies, focusing on intellectual property and corporate transactions in life sciences.

“Arvind and Aubrey bring a tremendous amount of talent and experience to our company, especially in the finance, strategy, and legal disciplines,” said Ken Song, M.D., President and CEO of RayzeBio. “Their expertise will be invaluable as we continue to build a leading radiopharmaceutical company.”

Arvind added, “RayzeBio is revolutionizing the field of targeted radiopharmaceuticals. I am honored and excited to be part of this amazing team.”

Aubrey further added, “The company is making tremendous strides in unlocking the potential of radiopharmaceuticals. I look forward to partnering with the rest of management team to advance the Company’s mission.”

About RayzeBio

RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.